Prognostic factors in patients with small cell lung carcinoma
Background The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment. Methods We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2010-06, Vol.27 (2), p.237-241 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 241 |
|---|---|
| container_issue | 2 |
| container_start_page | 237 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 27 |
| creator | Arinc, S. Gonlugur, U. Devran, O. Erdal, N. Ece, F. Ertugrul, M. Derince, D. Oruc, O. Hazar, A. |
| description | Background
The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment.
Methods
We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLC patients initially presented with limited disease, while 92 small cell lung carcinoma patients were found to be extensive.
Results
The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (≤4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors.
Conclusions
Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLC patients. |
| doi_str_mv | 10.1007/s12032-009-9198-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733934075</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2376354601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-5ea9db5a2db0e330c20c112379962050bbfa2881d1d081fff4d632eb4aa6d0583</originalsourceid><addsrcrecordid>eNp9kU9LxDAQxYMo7rr6AbxI8aKX6kzStM3Bgyz-gwU9KHgLaZquXbbpmrSI396ULiwIepkMzC9vXvIIOUW4QoDs2iMFRmMAEQsUeZzvkSlyLmJk-L4fesazGHgKE3Lk_QqAIqfikExQMCFSzqbk5sW1S9v6rtZRpXTXOh_VNtqorja289FX3X1EvlHrdaRNKOveLiOtnK5t26hjclCptTcn23NG3u7vXueP8eL54Wl-u4h1AqyLuVGiLLiiZQGGMdAUNCJlWTBBgUNRVIrmOZZYQo5VVSVlyqgpEqXSEnjOZuRi1N249rM3vpNN7Qc_ypq29zJjTLAEMh7Iy39JBJoDFRTTgJ7_Qldt72x4h8wzCpnADAKEI6Rd670zldy4ulHuOyjJIQQ5hiBDCHIIQQ5uz7bCfdGYcndj--sBoCPgw8gujdtt_lv1ByUokFY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872079170</pqid></control><display><type>article</type><title>Prognostic factors in patients with small cell lung carcinoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Arinc, S. ; Gonlugur, U. ; Devran, O. ; Erdal, N. ; Ece, F. ; Ertugrul, M. ; Derince, D. ; Oruc, O. ; Hazar, A.</creator><creatorcontrib>Arinc, S. ; Gonlugur, U. ; Devran, O. ; Erdal, N. ; Ece, F. ; Ertugrul, M. ; Derince, D. ; Oruc, O. ; Hazar, A.</creatorcontrib><description>Background
The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment.
Methods
We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLC patients initially presented with limited disease, while 92 small cell lung carcinoma patients were found to be extensive.
Results
The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (≤4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors.
Conclusions
Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLC patients.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-009-9198-8</identifier><identifier>PMID: 19399653</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Age ; Aged ; Antineoplastic Agents - therapeutic use ; Chemotherapy ; Chest ; Female ; Hematology ; Hospitals ; Humans ; Internal Medicine ; Lactic acid ; Leukocytes ; Lung cancer ; Lung Neoplasms - diagnosis ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Male ; Medicine ; Medicine & Public Health ; Metastases ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Prognosis ; Retrospective Studies ; small cell lung carcinoma ; Small Cell Lung Carcinoma - diagnosis ; Small Cell Lung Carcinoma - drug therapy ; Small Cell Lung Carcinoma - mortality ; Survival Rate - trends</subject><ispartof>Medical oncology (Northwood, London, England), 2010-06, Vol.27 (2), p.237-241</ispartof><rights>Humana Press Inc. 2009</rights><rights>Springer Science+Business Media, LLC 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-5ea9db5a2db0e330c20c112379962050bbfa2881d1d081fff4d632eb4aa6d0583</citedby><cites>FETCH-LOGICAL-c403t-5ea9db5a2db0e330c20c112379962050bbfa2881d1d081fff4d632eb4aa6d0583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-009-9198-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-009-9198-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19399653$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arinc, S.</creatorcontrib><creatorcontrib>Gonlugur, U.</creatorcontrib><creatorcontrib>Devran, O.</creatorcontrib><creatorcontrib>Erdal, N.</creatorcontrib><creatorcontrib>Ece, F.</creatorcontrib><creatorcontrib>Ertugrul, M.</creatorcontrib><creatorcontrib>Derince, D.</creatorcontrib><creatorcontrib>Oruc, O.</creatorcontrib><creatorcontrib>Hazar, A.</creatorcontrib><title>Prognostic factors in patients with small cell lung carcinoma</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Background
The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment.
Methods
We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLC patients initially presented with limited disease, while 92 small cell lung carcinoma patients were found to be extensive.
Results
The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (≤4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors.
Conclusions
Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLC patients.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Chemotherapy</subject><subject>Chest</subject><subject>Female</subject><subject>Hematology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lactic acid</subject><subject>Leukocytes</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>small cell lung carcinoma</subject><subject>Small Cell Lung Carcinoma - diagnosis</subject><subject>Small Cell Lung Carcinoma - drug therapy</subject><subject>Small Cell Lung Carcinoma - mortality</subject><subject>Survival Rate - trends</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU9LxDAQxYMo7rr6AbxI8aKX6kzStM3Bgyz-gwU9KHgLaZquXbbpmrSI396ULiwIepkMzC9vXvIIOUW4QoDs2iMFRmMAEQsUeZzvkSlyLmJk-L4fesazGHgKE3Lk_QqAIqfikExQMCFSzqbk5sW1S9v6rtZRpXTXOh_VNtqorja289FX3X1EvlHrdaRNKOveLiOtnK5t26hjclCptTcn23NG3u7vXueP8eL54Wl-u4h1AqyLuVGiLLiiZQGGMdAUNCJlWTBBgUNRVIrmOZZYQo5VVSVlyqgpEqXSEnjOZuRi1N249rM3vpNN7Qc_ypq29zJjTLAEMh7Iy39JBJoDFRTTgJ7_Qldt72x4h8wzCpnADAKEI6Rd670zldy4ulHuOyjJIQQ5hiBDCHIIQQ5uz7bCfdGYcndj--sBoCPgw8gujdtt_lv1ByUokFY</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Arinc, S.</creator><creator>Gonlugur, U.</creator><creator>Devran, O.</creator><creator>Erdal, N.</creator><creator>Ece, F.</creator><creator>Ertugrul, M.</creator><creator>Derince, D.</creator><creator>Oruc, O.</creator><creator>Hazar, A.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>20100601</creationdate><title>Prognostic factors in patients with small cell lung carcinoma</title><author>Arinc, S. ; Gonlugur, U. ; Devran, O. ; Erdal, N. ; Ece, F. ; Ertugrul, M. ; Derince, D. ; Oruc, O. ; Hazar, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-5ea9db5a2db0e330c20c112379962050bbfa2881d1d081fff4d632eb4aa6d0583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Chemotherapy</topic><topic>Chest</topic><topic>Female</topic><topic>Hematology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lactic acid</topic><topic>Leukocytes</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>small cell lung carcinoma</topic><topic>Small Cell Lung Carcinoma - diagnosis</topic><topic>Small Cell Lung Carcinoma - drug therapy</topic><topic>Small Cell Lung Carcinoma - mortality</topic><topic>Survival Rate - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arinc, S.</creatorcontrib><creatorcontrib>Gonlugur, U.</creatorcontrib><creatorcontrib>Devran, O.</creatorcontrib><creatorcontrib>Erdal, N.</creatorcontrib><creatorcontrib>Ece, F.</creatorcontrib><creatorcontrib>Ertugrul, M.</creatorcontrib><creatorcontrib>Derince, D.</creatorcontrib><creatorcontrib>Oruc, O.</creatorcontrib><creatorcontrib>Hazar, A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arinc, S.</au><au>Gonlugur, U.</au><au>Devran, O.</au><au>Erdal, N.</au><au>Ece, F.</au><au>Ertugrul, M.</au><au>Derince, D.</au><au>Oruc, O.</au><au>Hazar, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors in patients with small cell lung carcinoma</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>27</volume><issue>2</issue><spage>237</spage><epage>241</epage><pages>237-241</pages><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Background
The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment.
Methods
We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLC patients initially presented with limited disease, while 92 small cell lung carcinoma patients were found to be extensive.
Results
The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (≤4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors.
Conclusions
Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLC patients.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>19399653</pmid><doi>10.1007/s12032-009-9198-8</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2010-06, Vol.27 (2), p.237-241 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733934075 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Age Aged Antineoplastic Agents - therapeutic use Chemotherapy Chest Female Hematology Hospitals Humans Internal Medicine Lactic acid Leukocytes Lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Medicine Medicine & Public Health Metastases Middle Aged Oncology Original Paper Pathology Prognosis Retrospective Studies small cell lung carcinoma Small Cell Lung Carcinoma - diagnosis Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - mortality Survival Rate - trends |
| title | Prognostic factors in patients with small cell lung carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A16%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20in%20patients%20with%20small%20cell%20lung%20carcinoma&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Arinc,%20S.&rft.date=2010-06-01&rft.volume=27&rft.issue=2&rft.spage=237&rft.epage=241&rft.pages=237-241&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-009-9198-8&rft_dat=%3Cproquest_cross%3E2376354601%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=872079170&rft_id=info:pmid/19399653&rfr_iscdi=true |